BTMD - Company ID 0001819253
biote Corp. trades as BTMD. In its fiscal 2025 annual report the company posted revenue of $192.22M, down 2.5% from the prior year and net income of $27.05M. This page tracks biote Corp. through 398 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 4 fiscal years biote Corp.'s revenue grew from $139.40M to $192.22M, a compound annual growth rate of 8.4%. Net profit margin expanded from 8.0% to 14.1% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-18 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-13 |
| Insider trade | 4 | 2026-05-13 |
| Insider trade | 4 | 2026-05-13 |
| Insider trade | 4 | 2026-05-13 |
| Insider trade | 4 | 2026-05-13 |
| SCHEDULE 13G/A | - | 2026-05-13 |
The largest companies sharing biote Corp.'s SEC industry classification (medicinal chemicals & botanical products).
biote Corp. reported revenue of $192.22M for fiscal year 2025, a decrease of 2.5% year over year.
Yes. biote Corp. reported net income of $27.05M in its latest fiscal year.